Regulus Therapeutics Inc. (RGLS)
Regulus Therapeutics Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Diego, CA, US. The stock last traded at $8.16, up 0.00% on the session, giving a market capitalisation of $565.0M. On trailing twelve-month figures it carries a trailing P/E of -9.95, a net margin of 0.0%. Its beta of 0.37 implies it has historically moved less than the broad market.
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Regulus Therapeutics Inc. is most often compared with the following Healthcare names: